These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 33671836)
21. Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. Matta J; Baratin M; Chiche L; Forel JM; Cognet C; Thomas G; Farnarier C; Piperoglou C; Papazian L; Chaussabel D; Ugolini S; Vély F; Vivier E Blood; 2013 Jul; 122(3):394-404. PubMed ID: 23687088 [TBL] [Abstract][Full Text] [Related]
22. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. Zhang T; Wu MR; Sentman CL J Immunol; 2012 Sep; 189(5):2290-9. PubMed ID: 22851709 [TBL] [Abstract][Full Text] [Related]
23. Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression. Kim N; Yi E; Lee E; Park HJ; Kim HS Front Immunol; 2024; 15():1388018. PubMed ID: 38698855 [TBL] [Abstract][Full Text] [Related]
24. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. Brandt CS; Baratin M; Yi EC; Kennedy J; Gao Z; Fox B; Haldeman B; Ostrander CD; Kaifu T; Chabannon C; Moretta A; West R; Xu W; Vivier E; Levin SD J Exp Med; 2009 Jul; 206(7):1495-503. PubMed ID: 19528259 [TBL] [Abstract][Full Text] [Related]
25. A soluble fragment of the tumor antigen BCL2-associated athanogene 6 (BAG-6) is essential and sufficient for inhibition of NKp30 receptor-dependent cytotoxicity of natural killer cells. Binici J; Hartmann J; Herrmann J; Schreiber C; Beyer S; Güler G; Vogel V; Tumulka F; Abele R; Mäntele W; Koch J J Biol Chem; 2013 Nov; 288(48):34295-303. PubMed ID: 24133212 [TBL] [Abstract][Full Text] [Related]
26. Liu X; Guo R; Xu Y Genet Test Mol Biomarkers; 2021 Jul; 25(7):463-470. PubMed ID: 34280008 [No Abstract] [Full Text] [Related]
27. Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction. Müller T; Schlahsa L; Zhang HJ; Skaik Y; Eiz-Vesper B; Immenschuh S; Blasczyk R; Figueiredo C J Biol Regul Homeost Agents; 2014; 28(2):183-93. PubMed ID: 25001651 [TBL] [Abstract][Full Text] [Related]
28. Affinity Maturation of the Natural Ligand (B7-H6) for Natural Cytotoxicity Receptor NKp30 by Yeast Surface Display. Zielonka S; Krah S; Arras P; Lipinski B; Zimmermann J; Boje AS; Klausz K; Peipp M; Pekar L Methods Mol Biol; 2023; 2681():231-248. PubMed ID: 37405651 [TBL] [Abstract][Full Text] [Related]
29. All-trans retinoic acid induces leukemia resistance to NK cell cytotoxicity by down-regulating B7-H6 expression via c-Myc signaling. Cao G; Cheng Y; Zheng X; Wei H; Tian Z; Sun R; Sun H Cancer Commun (Lond); 2021 Jan; 41(1):51-61. PubMed ID: 34236140 [TBL] [Abstract][Full Text] [Related]
30. The B7 Family Member B7-H6: a New Bane of Tumor. Chen Y; Mo J; Jia X; He Y Pathol Oncol Res; 2018 Oct; 24(4):717-721. PubMed ID: 29086181 [TBL] [Abstract][Full Text] [Related]
31. The potential of B7-H6 as a therapeutic target in cancer immunotherapy. Mohammadi A; Najafi S; Amini M; Mansoori B; Baghbanzadeh A; Hoheisel JD; Baradaran B Life Sci; 2022 Sep; 304():120709. PubMed ID: 35697295 [TBL] [Abstract][Full Text] [Related]
32. Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma. Mantovani S; Oliviero B; Lombardi A; Varchetta S; Mele D; Sangiovanni A; Rossi G; Donadon M; Torzilli G; Soldani C; Porta C; Pedrazzoli P; Chiellino S; Santambrogio R; Opocher E; Maestri M; Bernuzzi S; Rossello A; Clément S; De Vito C; Rubbia-Brandt L; Negro F; Mondelli MU Hepatology; 2019 Mar; 69(3):1165-1179. PubMed ID: 30153337 [TBL] [Abstract][Full Text] [Related]
33. Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. Jarahian M; Fiedler M; Cohnen A; Djandji D; Hämmerling GJ; Gati C; Cerwenka A; Turner PC; Moyer RW; Watzl C; Hengel H; Momburg F PLoS Pathog; 2011 Aug; 7(8):e1002195. PubMed ID: 21901096 [TBL] [Abstract][Full Text] [Related]
34. Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack. Wang W; Guo H; Geng J; Zheng X; Wei H; Sun R; Tian Z J Biol Chem; 2014 Nov; 289(48):33311-9. PubMed ID: 25315772 [TBL] [Abstract][Full Text] [Related]
35. The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells. Textor S; Bossler F; Henrich KO; Gartlgruber M; Pollmann J; Fiegler N; Arnold A; Westermann F; Waldburger N; Breuhahn K; Golfier S; Witzens-Harig M; Cerwenka A Oncoimmunology; 2016 Jul; 5(7):e1116674. PubMed ID: 27622013 [TBL] [Abstract][Full Text] [Related]
36. B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. Pesce S; Tabellini G; Cantoni C; Patrizi O; Coltrini D; Rampinelli F; Matta J; Vivier E; Moretta A; Parolini S; Marcenaro E Oncoimmunology; 2015 Apr; 4(4):e1001224. PubMed ID: 26137398 [TBL] [Abstract][Full Text] [Related]